Get started

Biogen Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

BIIB chart

Key stats

Market capitalization
37.372BUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
13.89
Basic EPS (TTM)
18.45USD
Net income
3.047BUSD
Revenue
9.433BUSD
Shares float
143.938M
Beta
0.03

About Biogen Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Christopher A. Viehbacher
Website
biogen.com
Headquarters
Cambridge
Employees
8.725K
Founded
1978
ISIN
US09062X1037

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Ideas

BIIB Overdue for Gap UpBIIB's at a support level, but it's also been gapping up significantly every 2-6 quarters for the past few years. Its last gap was exactly a year ago, so it's overdue for a gap up. It's also within a month of earnings, so management is likely keen on pushing for newsworthy developments. I'll be roll
Long
$BIIB: Monster trade, brace yourselvesBiogen has a monster trade brewing here, can't afford to miss this trade. I've been trading it actively since they received FDA approval for their Alzheimer's drug a while back. The current setup looks very strong and implies a massive uptrend can start from right here. Best of luck! Ivan Labrie
Long
6
Biogen testing channel supportBiogen Inc. (BIIB) currently testing channel support, able to absorb weekly selling pressures. From here, (BIIB) can recover and turn higher to channel resistance, eliciting gains of 20-25% over the following 2 - 3 months. A settlement above this week’s high would accelerate this upward momentum
BIIB earningsBiogen (BIIB) earnings are on Wednesday, July 19th, 2023, at 7:15am. Biogen (BIIB) reported Q1 March 2023 earnings of 3.40 per share on revenue of 2.5 billion. The consensus earnings estimate was 3.25 per share on revenue of 2.4 billion. The company said it continues to expect 2023 earnings of 15.00
Long
BIIB consolidation might get to end and a new move up possible.BIIB shares might the consolidation channel and prepare a move higher. The reason would be that the market discounts the potential sales CAGR for Alzheimer's drugs, reimbursements being an issue. If the problem gets solved, BIIB gets a clear path towards higher valuation.
Long
BIIB - Head and ShouldersOn the chart, we can see a head and shoulders forming. It's currently at the neckline, from which a breakout will activate our short position. Both MACD and RSI are showing bearish crossings. More info is shown on the chart. Good luck!
1
Alzheimer's drug, from $BIIB and EisaiAccording to MarketWatch, The FDA approved the Alzheimer's drug Legembi from Eisai and Biogen A quick look at the daily charts for $BIIB shows that it's already trading on or above major moving averages (ie. 9,21,50 SMA's). Also, seeing as this is a nice, green day for the SPY and BIIB has been bea
Long
BIIB ShortIn downtrend, bounced back to Supply zone Current Monthly chart price range 73 - 217 Earning 7/26/2022 Estimate 4.09 Short 200 Stop 220 Target 140 Risk management is much more important than a good entry point. I am not a PRO trader. In my trading plan, the Max Risk of each short term trade shoul
3

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers 

Sparks

Curated watchlists where BIIB is featured.

See all sparks